TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20085491
Drug: Optimized background
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized background therapy alone
Study: 19526756
Drug: Shengmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai Injection (SMI)
Study: 10543335
Drug: tolterodine 2
Normalized name: tolterodine 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine 2 mg twice daily
Study: 10543335
Drug: oxybutynin 5
Normalized name: oxyBUTYnin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxybutynin 5 mg three times daily
Study: 1938567
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with four heat treatments
Study: 1938567
Drug: Radiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy combined with one heat treatment
Study: 7278083
Drug: Cimetidine 10
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 10 mg intravenously
Study: 7278083
Drug: Cimetidine high
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine high dose (not specified)
Study: 25295663
Drug: Oral hydrogen-rich
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrogen-rich tablets (2 g per day)
Study: 25295663
Drug: Oral hydrogen-rich
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydrogen-rich tablets (2 g per day) and topical hydrogen-rich packs (6 times per day for 20 minutes)
Study: 25295663
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional treatment protocol for soft tissue injury)
Study: 19766645
Drug: PegIFNalpha2a plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNalpha2a plus RBV 800-1200 mg/day
Study: 19766645
Drug: PegIFNalpha2b plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegIFNalpha2b plus RBV 800-1200 mg/day
Study: 9422572
Drug: 3.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 Gy daily fractions
Study: 9422572
Drug: bio-average and
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: bio-average and bio-maximum dose (corrected for fraction size)
Study: 9422572
Drug: uncorrected dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: uncorrected dose distributions
Study: 28328347
Drug: CSL830 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL830 40 IU/kg twice weekly
Study: 28328347
Drug: CSL830 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL830 60 IU/kg twice weekly
Study: 25833063
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (4 ml/kg body weight, 0.48 g/kg of alcohol 12%, corresponding to 2-3 glasses/daily) and extra-virgin olive oil (treatment A)
Study: 25833063
Drug: Extra-virgin olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra-virgin olive oil alone (treatment B)
Study: 25833063
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine and extra-virgin olive oil (treatment A)
Study: 23517291
Drug: Desvenlafaxine 10
Normalized name: desvenlafaxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 10 mg/day
Study: 23517291
Drug: Desvenlafaxine 10
Normalized name: desvenlafaxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 10 mg/day and 50 mg/day
Study: 16621868
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day ezetimibe (Group A)
Study: 16621868
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day ezetimibe as an add-on to 20 mg/day simvastatin (Group B)
Study: 16621868
Drug: Dose escalation
Normalized name: PALFORZIA Initial Dose Escalation KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation from 10 to 40 mg/day atorvastatin (Group C)
Study: 16621868
Drug: De novo
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De novo monotherapy with 40 mg/day atorvastatin (Group D)
Study: 11371418
Drug: Control oral
Normalized name: Dayquil Mucus Control Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oral plate (A)
Study: 9296410
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 0, 25, 50, or 75 microg x kg(‐1) x min(‐1)
Study: 9296410
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion at 50-75 microg x kg(‐1) x min(‐1)
Study: 9296410
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion of 25-50 microg x kg(‐1) x min(‐1) in combination with alfentanil infusion of 0.2-0.4 microg x kg(‐1) x min(‐1)
Study: 8289986
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g elemental calcium per day
Study: 29417623
Drug: Sarcosine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarcosine (2 g daily)
Study: 24507630
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) for PTSD (n = 30)
Study: 24507630
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment (n = 29)
Study: 20854144
Drug: etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etravirine 200 mg twice-daily
Study: 17646601
Drug: UFH dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH dosage of 5000 U 3 times daily
Study: 10665629
Drug: Paroxetine (20‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20‐60 mg/day)
Study: 10665629
Drug: Clomipramine (50‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (50‐150 mg/day)
Study: 10665629
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy (12 sessions)
Study: 8690817
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg every 8 hours for 8 days) after a standardized 602-calorie, high-fat breakfast
Study: 8690817
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg every 8 hours for 8 days) after an overnight fast
Study: 2060542
Drug: Simvastatin 30
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 30 mg/day
Study: 6196822
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 (1000-1500 ml) with Ringer's acetate solution (2000-3000 ml)
Study: 6196822
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate alone (5000-8000 ml)
Study: 2492325
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue-type plasminogen activator (rt-PA, 150 mg/8 h)
Study: 2492325
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue-type plasminogen activator (rt-PA) in patients with intracoronary thrombus
Study: 2492325
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue-type plasminogen activator (rt-PA) in patients without thrombus
Study: 29978790
Drug: rESWT (radial
Approvals — FDA: no, EMA: no, PMDA: no
Description: rESWT (radial extracorporeal shockwave therapy) for 1 cycle
Study: 29978790
Drug: Local hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local hormone injection for 1 cycle
Study: 25087182
Drug: Asparaginase and
Normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asparaginase and steroids
Study: 25087182
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of asparaginase and steroids
Study: 25087182
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of ALL therapy
Study: 20636856
Drug: Magnetic film
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic film array application of 5% urea gel
Study: 20636856
Drug: Passive occluded
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive occluded application of 5% urea gel with plastic occlusive film and non-magnetic film
Study: 15745837
Drug: Postprandial strategy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial strategy: premeal insulin lispro with basal insulin at bedtime (NPH insulin), targeting 2‐h PPBG < or = 7.5 mmol/l
Study: 15745837
Drug: Basal strategy:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal strategy: insulin (NPH insulin twice daily or insulin glargine once daily; or premixed human insulin (70% NPH/30% regular; 30/70) twice daily), targeting fasting and premeal blood glucose (BG; < or = 6.7 mmol/l)
Study: 2268486
Drug: HD with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HD with a sodium profile (140‐148 mmol/L)
Study: 2268486
Drug: Conventional HD
Normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional HD (dialysate sodium 140 mmol/L)
Study: 31915861
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of CBD for 1 week
Study: 25261342
Drug: Opioid antagonist
Normalized name: OPIOID ANTAGONIST ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid antagonist (50 mg naltrexone)
Study: 20443645
Drug: Sequential use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential use of pharmacotherapy and psychotherapy
Study: 20443645
Drug: Clinical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical management and treatment as usual
Study: 17876994
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs), particularly fluoxetine
Study: 17876994
Drug: Fluvoxamine, paroxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine, paroxetine, and sertraline (SSRIs available in Japan)
Study: 16128368
Drug: Aprotinin (15,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (15,000 KIU/min) administered in the pulmonary artery
Study: 10566553
Drug: RCP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCP level > or = 1.0 ng/ml
Study: 2006653
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg plus Amiloride 2.5 mg
Study: 27003595
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (PFMT) over 3 months (12 weekly sessions)
Study: 27003595
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no specific LUTS treatment)
Study: 24731890
Drug: 6-week stress
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week stress management programme (relaxation breathing and progressive muscle relaxation, RB-PMR, twice a day) (N=31)
Study: 20655946
Drug: Project Towards
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Project Towards No Drug Abuse (TND) program with regular workshop training
Study: 20655946
Drug: Project Towards
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Project Towards No Drug Abuse (TND) program with comprehensive implementation support
Study: 17434541
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg cinnarizine (CIN)
Study: 11956258
Drug: ECF (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECF (epirubicin 50 mg/m(2) every 3 weeks, cisplatin 60 mg/m(2) every 3 weeks, PVI 5‐FU 200 mg/m(2)/d)
Study: 11956258
Drug: MCF (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCF (mitomycin 7 mg/m(2) every 6 weeks, cisplatin 60 mg/m(2) every 3 weeks, PVI 5‐FU 300 mg/m(2)/d)
Study: 9708225
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day etidronate for 14 days followed by calcium (97 mg elemental Ca/day) and vitamin D (400 IU) for 76 days, repeated for 2 years
Study: 9708225
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 14 days followed by calcium (97 mg elemental Ca/day) and vitamin D (400 IU) for 76 days, repeated for 2 years
Study: 29911321
Drug: Fractional CO2-laser
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2-laser treatment (two sessions in a 4-week interval)
Study: 29911321
Drug: Fractional CO2-laser
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2-laser treatment
Study: 28901116
Drug: Tripterygium glycosides
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium glycosides combined with Danshen injection
Study: 20137366
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with sufentanil 0.5 microg/ml
Study: 20137366
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with sufentanil 0.5 microg/ml
Study: 20137366
Drug: Levobupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine with sufentanil 0.5 microg/ml
Study: 10554373
Drug: Short-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course antibiotic therapy (24 hours)
Study: 10554373
Drug: Long-course antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course antibiotic therapy (5 days)
Study: 8556837
Drug: Epoetin beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Epoetin beta administered subcutaneously either daily or thrice weekly
Study: 1789812
Drug: Simvastatin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (2.5 to 40 mg q.p.m.)
Study: 7326162
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl anaesthesia (75 micrograms kg‐1)
Study: 7326162
Drug: Incremental doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental doses of papaveretum
Study: 28384752
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of NP001
Study: 26513587
Drug: alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: alcohol (0.8 g/kg)
Study: 26513587
Drug: delta-9-tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: delta-9-tetrahydrocannabinol (THC) (7.5 mg)
Study: 19699834
Drug: Mean daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean daily energy intake
Study: 9754848
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tolperisone hydrochloride
Study: 9754848
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg tolperisone hydrochloride
Study: 579654
Drug: Holoxan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holoxan therapy
Study: 30221615
Drug: DREAMS-START intervention
Normalized name: Dream Pure BB
Approvals — FDA: no, EMA: no, PMDA: no
Description: DREAMS-START intervention (six-session manualized therapy)
Study: 24033650
Drug: Computerized aphasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized aphasia therapy
Study: 21876444
Drug: Crushed lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed lopinavir/ritonavir tablets (200/50 mg)
Study: 21876444
Drug: Whole lopinavir/ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole lopinavir/ritonavir tablets (200/50 mg)
Study: 19682886
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 50 microg
Study: 19682886
Drug: SYS group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYS group (Intravenous fentanyl 50 microg)
Study: 16939523
Drug: PEG‐Intron 3‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐Intron 3‐6 microg kg(‐1) administered subcutaneously once a week
Study: 15472204
Drug: Canrenoate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenoate (200 mg injections)
Study: 11576570
Drug: Norethindrone-containing pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone-containing pills
Study: 11576570
Drug: Desogestrel-containing pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing pills
Study: 3503390
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of OK-432 (ID Group)
Study: 3503390
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of OK-432 (IM Group)
Study: 31388792
Drug: AT-101 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-101 (40 mg) every 12 h on days 1, 2, and 3 combined with paclitaxel (150 mg/m2) and carboplatin (AUC 5) at DL1
Study: 31388792
Drug: AT-101 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-101 (40 mg) every 12 h on days 1, 2, and 3 combined with paclitaxel (175 mg/m2) and carboplatin (AUC 6) at DL2
Study: 26607848
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg total: two 40 mg capsules 1 hour prior to extraction and one 40 mg capsule postoperatively)
Study: 26607848
Drug: Propranolol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (120 mg total)
Study: 24047916
Drug: High-Protein (HP)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Protein (HP) diet (≥90 g protein/d)
Study: 19515530
Drug: 1% ISDN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ISDN in Vaseline applied to the dorsum of the affected hand four times daily for 10 weeks
Study: 19515530
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment applied to the dorsum of the affected hand four times daily for 10 weeks
Study: 15220683
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors, H2‐receptor antagonists, prokinetics, or antacids (specifics not detailed)
Study: 15220683
Drug: Therapy with
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with proton pump inhibitors, H2‐receptor antagonists, prokinetics, or antacids
Study: 11069315
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for active ulcerative colitis
Study: 11069315
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to treatment
Study: 2866830
Drug: Dezocine 15
Normalized name: dezocine 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine 15 mg
Study: 30548692
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg/day plus solifenacin 5 mg, propiverine 20 mg, imidafenacin 0.2 mg, or tolterodine 4 mg (with potential to double the antimuscarinic dose at week 8)
Study: 30548692
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg/day plus antimuscarinic therapy
Study: 30548692
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg/day plus propiverine
Study: 30548692
Drug: Mirabegron 50
Normalized name: mirabegron 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 50 mg/day plus tolterodine
Study: 29450494
Drug: Clinical Treatment
Normalized name: Clinicalm
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clinical Treatment Score
Study: 19558724
Drug: Speed of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speed of processing treatment
Study: 19558724
Drug: Memory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory treatment
Study: 19558724
Drug: Reasoning treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasoning treatment
Study: 15225189
Drug: 600 micro
Normalized name: Fentanyl 600 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 micro g misoprostol sublingually
Study: 15225189
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml syntometrine intravenously
Study: 2681086
Drug: Anandron 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anandron 300 mg daily
Study: 28946528
Drug: PNF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PNF treatment
Study: 28946528
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy (MAN.T)
Study: 23038624
Drug: Prednisolone 5
Normalized name: prednisolone 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 5 mg for 1 week
Study: 21804104
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose, 90 mg twice daily)
Study: 21804104
Drug: Clopidogrel (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300-600 mg loading dose, 75 mg daily)
Study: 19538732
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg/day, orally, for 12 months)
Study: 9056681
Drug: Nisoldipine CC
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine CC 10 mg
Study: 9056681
Drug: Nisoldipine CC
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine CC 20 mg
Study: 9056681
Drug: Nisoldipine CC
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine CC 30 mg